Stella Diagnostics logo

Stella Diagnostics(OTC) SLDX

Market Cap$3.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2008)-100%
5 Year-99%
1 Year-50%
1 Month+24%
$0.01
+0.00%
+0.00Today
Stella Diagnostics last closing stock price
MetricPriceDate
Last closeUSD 0.012026-10-01
Stella Diagnostics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+24.1%USD 0.012026-09-14
1 month+24.1%USD 0.012026-09-01
3 month-3.1%USD 0.012026-07-02
Year to date-35.4%USD 0.022025-12-31
1 year-50%USD 0.022025-10-01
3 year-90%USD 0.102023-09-28
5 year-98.67%USD 0.752021-10-01
Since inception-99.8%USD 5.002008-07-07

Stella Diagnostics Financials at a Glance

Market Cap

$3.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.69M

Net Income (TTM)

-$4.36M

EPS (TTM)

-$0.01

P/E Ratio

-0.71

Dividend

$0.00

Beta (Volatility)

0.59 (Low)

Price

$0.01

Volume

1,000

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.01 - $0.04

Estimated Earnings Date

N/A

SLDX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Stella Diagnostics

Stella Diagnostics Inc. is a molecular diagnostics company dedicated to improving patient care for individuals with severe esophageal disorders. The firm specializes in clinical tests that provide essential molecular insights, enabling physicians to assess disease progression and potential malignancy.

Products and Services
  • Specialized clinical tests for esophageal disorders
  • Innovative diagnostic tools for enhanced molecular insights
  • Research and development in molecular diagnostics
Growth Outlook
  • Recent quarterly revenue increased to $501,077, showing potential for growth
  • Trailing twelve months (TTM) revenue of $1,245,000 indicates a steady demand
  • Focus on expanding diagnostic capabilities may drive future revenue
Financial Highlights
  • Net income for Q2 2026 was -$978,006, reflecting ongoing investment in growth
  • Cash and cash equivalents decreased to $7,919, indicating liquidity challenges
  • Current liabilities significantly exceed current assets, highlighting financial risk
Stella Diagnostics Inc. operates in the healthcare sector, specifically within the medical diagnostics and research industry. The company has made strides in developing specialized tests that provide critical information about esophageal disorders, which can significantly impact patient treatment strategies. Despite facing financial challenges, including negative net income and liquidity issues, the recent revenue growth suggests a potential for recovery and expansion. The focus on innovative diagnostic tools positions the company to capitalize on the increasing demand for advanced medical diagnostics. Investors may find interest in the company's commitment to enhancing patient care through molecular insights, despite the current financial hurdles.
AI Generated • Sep 23, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

3

CEO

David Seaburg

Website

www.stelladx.com

Headquarters

Salt Lake City, UT 84101, US

SLDX Financials

Key Financial Metrics (TTM)

Gross Margin

-21.65%

Operating Margin

-243.70%

Net Income Margin

-258.33%

Return on Equity

15.97%

Return on Capital

N/A

Return on Assets

-3848.90%

Earnings Yield

-1.41%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

301.50M

Volume

1.00K

Avg. Volume

3.25K

Financials (TTM)

Gross Profit

-$364.94K

Operating Income

-$4.11M

EBITDA

-$4.11M

Operating Cash Flow

-$2.37M

Capital Expenditure

$0.00

Free Cash Flow

-$2.37M

Cash & ST Invst.

$7.92K

Total Debt

$14.12M

Stella Diagnostics Performance Analysis

Stella Diagnostics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 1,783,818N/A
Stella Diagnostics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-10.0%
Q42025-12-31-4.9%
Q12026-03-31-64.1%
Q22026-06-30183.8%
Stella Diagnostics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.03-80.2%
20232023-12-31USD -0.02-44.4%
20242024-12-31USD -0.00-83.7%
20252025-12-31USD -0.01277.4%
Stella Diagnostics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3035.5%
Q42025-12-31-165.0%
Q12026-03-3132.1%
Q22026-06-3011.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$501.08K

-12.8%

Gross Profit

-$70.56K

+77.4%

Gross Margin

-14.08%

N/A

Market Cap

$3.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.51M

N/A

Employees

2

N/A

Net Income

-$978.01K

+12.9%

EBITDA

-$889.53K

-27.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$7.92K

-78.5%

Total Debt

$14.12M

+440.0%

Accounts Receivable

$10.22K

+0.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$14.12M

+447.5%

Return on Assets

-38.49%

N/A

Return on Invested Capital

14.19%

N/A

Free Cash Flow

-$977.64K

-217.6%

Operating Cash Flow

-$977.64K

-217.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TDSGFTelo Genomics Corp.
$0.03+0.00%
TBRIFTherma Bright Inc.
$0.03-6.67%
CNGGFCann Group Limited
$0.00-20.28%
DOGPDogecoin Cash, Inc.
$0.01-2.86%

Trending Stocks

Symbol / CompanyPricePrice Chg
NKENike
$33.87-3.64%
NVDANvidia
$233.95+1.34%
SPCXSpace Exploration Technologies
$158.96+7.36%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$29.71-6.46%

Questions About SLDX

What is the current price of Stella Diagnostics?

Stella Diagnostics is trading at $0.01 per share.

What is the 52-week range for Stella Diagnostics?

Over the past 52 weeks, Stella Diagnostics has traded between $0.01 and $0.04.

How much debt does Stella Diagnostics have?

As of the most recent reporting period, Stella Diagnostics reported total debt of $14.12M.

How much cash does Stella Diagnostics have on hand?

Stella Diagnostics reported $7.92K in cash and cash equivalents in its most recent financial results.

What is Stella Diagnostics’s dividend yield?

Stella Diagnostics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services